LYSARC

Real-World Study Shows Axicabtagene Ciloleucel Outperforms Tisagenlecleucel in Relapsed/Refractory DLBCL

- A large French real-world study of 809 patients with relapsed/refractory DLBCL found axicabtagene ciloleucel (axi-cel) demonstrated superior efficacy compared to tisagenlecleucel (tisa-cel) with significantly higher response rates and improved survival outcomes. - After propensity score matching of 418 patients, axi-cel achieved 80.4% overall response rate and 60.3% complete response rate versus 66.0% and 42.1% respectively for tisa-cel, with one-year progression-free survival of 46.6% versus 33.2%. - The superior efficacy of axi-cel came with increased toxicity, including significantly higher rates of severe immune cell-associated neurotoxicity syndrome (13.9% vs 2.9%) and prolonged hematological toxicity. - This comprehensive analysis from the DESCAR-T registry provides the first real-world evidence of overall survival advantage for axi-cel over tisa-cel in third-line or later treatment of DLBCL.